{"id":40069,"date":"2025-09-26T11:36:29","date_gmt":"2025-09-26T06:36:29","guid":{"rendered":"https:\/\/menamedicalresearch.com\/news\/?p=40069"},"modified":"2025-09-26T11:36:29","modified_gmt":"2025-09-26T06:36:29","slug":"molecular-profiling-and-targeted-therapy-for-non-small-cell-lung-cancer-in-the-mena-region","status":"publish","type":"post","link":"https:\/\/menamedicalresearch.com\/news\/cancers\/molecular-profiling-and-targeted-therapy-for-non-small-cell-lung-cancer-in-the-mena-region\/","title":{"rendered":"Molecular Profiling and Targeted Therapy for Non-Small Cell Lung Cancer in the MENA Region"},"content":{"rendered":"<p>The <strong>treatment paradigm for advanced non-small cell lung cancer (NSCLC) has been fundamentally changed by the introduction of targeted therapies and immunotherapy<\/strong> over the past decade. Given that lung cancer remains a leading cause of global cancer mortality, understanding the regional molecular epidemiology is vital.<\/p>\n<p>This systematic review and expert opinion study aimed to determine the prevalence of key oncogenic mutations (<strong>ALK, EGFR, KRAS, ROS1, MET, BRAF, and HER2<\/strong>) in NSCLC patients across the Middle East and North Africa (<strong>MENA<\/strong>) region and evaluate current treatment approaches in the Gulf Cooperation Council (<strong>GCC<\/strong>). The study involved a systematic literature search, complemented by interviews with 10 medical oncologists from the GCC to provide real-world clinical context.<\/p>\n<p>Analysis of the pooled data revealed significant molecular patterns, underscoring the difference in mutation profiles compared to other global populations. <strong>EGFR<\/strong> mutations were found to be the most frequent driver in the MENA region, with a prevalence of <strong>24%<\/strong> (95% CI, 22.05-25.41%), followed by <strong>KRAS<\/strong> mutations at <strong>19.7%<\/strong> (95% CI, 15.29-24.07%). The prevalence rates for other mutations were <strong>ALK<\/strong> at <strong>7.9%<\/strong>, <strong>MET<\/strong> at <strong>4.7%<\/strong>, and <strong>BRAF<\/strong> at <strong>3.7%<\/strong>, with <strong>ROS1<\/strong> at <strong>2.2%<\/strong>. Data for HER2 mutations were not available.<\/p>\n<p>Experts noted that while targeted therapies and treatment protocols in GCC countries generally align with major international guidelines (NCCN, ESMO) and are well-funded by governmental healthcare systems, significant challenges remain. These primarily revolve around the standardization and implementation of comprehensive molecular diagnostics, such as Next-Generation Sequencing (NGS) and liquid biopsy, across the region.<\/p>\n<p>The study concludes that ongoing research is essential to fully characterize driver mutations across the wider MENA countries to further refine and inform future personalized treatment strategies.<\/p>\n<p><strong>Reference Source<br \/>\n<\/strong>AlJassim A, Kanbour A, Azribi F, et al. Prevalence of molecular mutations in non-small cell lung cancer and current treatment approaches in the MENA region: systematic review and expert opinion.<br \/>\n<em>J Immunother Precis Oncol<\/em>. Aug 26, 2025; 8:233-241. DOI: 10.36401\/\u041f\u0420\u041e-24-35.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The treatment paradigm for advanced non-small cell lung cancer (NSCLC) has been fundamentally changed by the introduction of targeted therapies and immunotherapy over the past decade. Given that lung cancer remains a leading cause of global cancer mortality, understanding the regional molecular epidemiology is vital. This systematic review and expert opinion study aimed to determine &hellip;<\/p>\n","protected":false},"author":1,"featured_media":40070,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[39],"tags":[],"class_list":["post-40069","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancers"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/menamedicalresearch.com\/news\/wp-json\/wp\/v2\/posts\/40069","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/menamedicalresearch.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/menamedicalresearch.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/menamedicalresearch.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/menamedicalresearch.com\/news\/wp-json\/wp\/v2\/comments?post=40069"}],"version-history":[{"count":1,"href":"https:\/\/menamedicalresearch.com\/news\/wp-json\/wp\/v2\/posts\/40069\/revisions"}],"predecessor-version":[{"id":40071,"href":"https:\/\/menamedicalresearch.com\/news\/wp-json\/wp\/v2\/posts\/40069\/revisions\/40071"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/menamedicalresearch.com\/news\/wp-json\/wp\/v2\/media\/40070"}],"wp:attachment":[{"href":"https:\/\/menamedicalresearch.com\/news\/wp-json\/wp\/v2\/media?parent=40069"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/menamedicalresearch.com\/news\/wp-json\/wp\/v2\/categories?post=40069"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/menamedicalresearch.com\/news\/wp-json\/wp\/v2\/tags?post=40069"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}